MyVisionTest News Archive
Jan 16, 2012
Regeneron, Genentech partially settle Eylea patent issue
Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release.
Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release said.
The agreement calls for Regeneron to pay Genentech based on U.S. sales of Eylea (aflibercept, Regeneron) through May 7, 2016, according to the release. Once sales reach $400 million, Regeneron will pay Genentech $60 million. When sales reach between $400 million and $3 billion, Regeneron will pay royalties of 4.75%. Once sales exceed $3 billion, Regeneron will pay royalties of 5.5%.
Litigation will continue with regard to patents not covered by the partial settlement agreement, according to the release.
The U.S. Food and Drug Administration approved Eylea, also known as VEGF Trap-Eye, for the treatment of neovascular age-related macular degeneration in December 2011 after a priority review.
In clinical trials, Eylea was as safe and effective in maintaining vision as Lucentis. Lucentis is injected monthly, while Eylea would only have to be injected every two months, making it more convenient for patients. Less frequent injections may also decrease the risk of adverse events related to the injection procedure, such as endophthalmitis and elevation of intraocular pressure.
Both drugs may face competition from Avastin (bevacizumab), a much less expensive medicine that is often used to treat macular degeneration even though it has not been approved by the FDA for that purpose.
Avastin also blocks angiogenesis, but the tiny amount needed for an eye injection costs only around $50, against a U.S. price of $1,950 for Lucentis and probably a similar price for Eylea.
Many doctors, particularly in the United States, already use Avastin off label to treat wet age-related macular degeneration. Analysts said more may start to prescribe it after the CATT study showed Avastin was as effective as Lucentis, though it had more side effects.
Read more...
OSN Supersite
Tags: VEGF Trap, Lucentis, Avastin, CATT
Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release.Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release said.
Litigation will continue with regard to patents not covered by the partial settlement agreement, according to the release.
The U.S. Food and Drug Administration approved Eylea, also known as VEGF Trap-Eye, for the treatment of neovascular age-related macular degeneration in December 2011 after a priority review.
In clinical trials, Eylea was as safe and effective in maintaining vision as Lucentis. Lucentis is injected monthly, while Eylea would only have to be injected every two months, making it more convenient for patients. Less frequent injections may also decrease the risk of adverse events related to the injection procedure, such as endophthalmitis and elevation of intraocular pressure.
Both drugs may face competition from Avastin (bevacizumab), a much less expensive medicine that is often used to treat macular degeneration even though it has not been approved by the FDA for that purpose.
Avastin also blocks angiogenesis, but the tiny amount needed for an eye injection costs only around $50, against a U.S. price of $1,950 for Lucentis and probably a similar price for Eylea.
Many doctors, particularly in the United States, already use Avastin off label to treat wet age-related macular degeneration. Analysts said more may start to prescribe it after the CATT study showed Avastin was as effective as Lucentis, though it had more side effects.
Read more...
OSN Supersite
